Ondine Biomedical Inc. appointed a new Board of Directors with considerable medtech and pharma expertise following its listing on the London AIM market. Key appointments include the Honourable Jean Charest, former Deputy Prime Minister of Canada, as Chairman, and Dr. Junaid Bajwa, the Chief Medical Scientist at Microsoft Research. Carolyn Cross, Founder and CEO of Ondine, and Nicolas G. Loebel, PhD, President and Chief Technology Officer, will remain on the Board. The new Chairman of the Board, the Honourable Jean Charest, is the former Deputy Prime Minister of Canada and the former Premier of the Province of Quebec. With a public service career spanning almost 30 years, Mr. Charest is one of Canada's best-known political figures; he was first elected to the House of Commons in 1984 and, at age 28, became Canada's youngest cabinet minister. Mr. Charest is a Partner with McCarthy Thetrault and remains active in public policy and community activities. Jean Duvall joins Ondine as non-executive Director and Senior Independent Director. Ms. Duvall is Co-Founder and was Chair of cell and gene therapy specialist, Trizell Holding, and initiated and drove Ferring's entry into gene and cell therapy by leading the acquisition of assets and founding of Trizell. Dr Junaid Bajwa joins as a non-executive Director. Dr Bajwa is the Chief Medical Scientist at Microsoft Research and a practising NHS physician. He was previously the Global Lead for Strategic Alliances and Solutions for the Global Digital Centre of Excellence at Merck Sharp & Dohme, and also co-founded "VelocityHealth" as Europe's first prevention focused digital-health accelerator, in partnership with Telefonica. Management consultant and ex. NHS Confederation CEO Mike Farrar also joins as a non-executive Director. Mr. Farrar stepped down as the Chief Executive of the NHS Confederation in September 2013 and remains a prominent thought leader and consultant to the NHS. He has worked as an independent consultant, with clients such as Celesio, RCGP, ABPI, NHS Quest, NHS Leadership Academy, Health Foundation, Pfizer, CIPFA, as well as starting up a number of small companies aimed at promoting health innovations. Dr Simon Sinclair is appointed a non-executive Director. Dr Sinclair is a senior executive physician scientist with over 15 years' pharma, medtech and consumer healthcare industry experience. He is currently Chief Safety Officer at Reckitt. Dr. Sinclair was previously at Johnson and Johnson Medical Devices, first as International Clinical Director, then leading Medical Affairs for its EMEA region. Prior to this, Dr. Sinclair led translational medicine efforts and the early clinical development at Merck and Co (MSD) in the USA. Finally, Craig Tooman is also appointed as non-executive Director. Mr. Tooman has more than 30 years of experience in the biopharmaceutical industry, including 15 years of experience as a public company CFO. He is currently CFO at Silence Therapeutics, and recently served as CFO and COO at Vyome Therapeutics. Prior to this Mr. Tooman was CFO and then CEO of Aratana Therapeutics where he successfully negotiated a merger with Elanco.